BioMarin bets $275 million on oral treatment for rare bone disease
The rare disease drug market has long run on injectable therapies, a delivery format patients tolerate but rarely prefer. Against that backdrop, BioMarin Pharmaceutical announced Tuesday it has entered a definitive agreement to…
Key takeaways
- BioMarin Pharmaceutical announced Tuesday a definitive agreement to acquire Alesta Therapeutics for $275 million upfront plus up to $215 million in milestone payments.
- The acquired asset, ALE1, is an orally active small molecule to treat hypophosphatasia (HPP), a rare genetic disorder caused by ALPL gene mutations that impairs bone and tooth mineralization.
- ALE1 is in an early Phase 1/2a trial assessing safety, tolerability, and pharmacokinetics in healthy volunteers and adults with HPP, and has not yet confirmed efficacy.
- If approved, ALE1 would be the first oral therapy for HPP, since every currently approved HPP treatment is injectable.
- The deal, approved by both boards and funded with cash on hand, is expected to close in the third quarter of 2026.
The rare disease drug market has long run on injectable therapies, a delivery format patients tolerate but rarely prefer. Against that backdrop, BioMarin Pharmaceutical announced Tuesday it has entered a definitive agreement to acquire Alesta Therapeutics for $275 million upfront, with up to $215 million in additional payments tied to development and regulatory milestones.
The target asset is ALE1, an orally active small molecule designed to treat hypophosphatasia, or HPP. HPP is a rare genetic disorder caused by mutations in the ALPL gene, impairing bone and tooth mineralization and, in adults, contributing to muscle weakness, fatigue, and pain. The condition has been diagnosed in more than 9,000 Americans, though it is thought to be more widespread than current figures reflect.
ALE1 is in a Phase 1/2a clinical trial evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers and adults with HPP. The program is early. That trial stage tells you the drug is safe enough to study at scale and gives a preliminary pharmacokinetic picture; it does not confirm efficacy. BioMarin is acquiring a mechanism and a runway, not a late-stage asset ready to file.
The drug works by inhibiting a target that regulates levels of inorganic pyrophosphate, the metabolite at the center of HPP's disease pathway. Reducing excess pyrophosphate is designed to restore bone and mineral metabolism. If approved, ALE1 would be the first oral therapy for the condition. Every currently approved HPP treatment is injectable.
BioMarin President and CEO Alexander Hardy said the deal brings a potential oral alternative to current injectable options while strengthening the company's early-stage clinical pipeline. Alesta CEO Ilan Ganot said BioMarin's global reach and rare disease track record made it the right buyer to advance the program.
Under the terms, Alesta will spin out all non-ALE1 assets before the transaction closes, and no Alesta employees will join BioMarin. The company said it plans to fund the acquisition with cash on hand. Both boards have approved the deal, which is expected to close in the third quarter of 2026. Morgan Stanley is advising BioMarin; J.P. Morgan Securities is advising Alesta.
The acquisition is BioMarin's third major deal in the rare disease space over the past year, according to CNBC, a pace that fits the sector-wide pattern of larger franchises absorbing early clinical assets they can carry through late-stage development. For ALE1, the read-through is plain: Phase 1/2a data is a clue about the molecule's behavior in humans, not a verdict on whether it reaches patients.
Source · 來源